JENBURKT PHARMACEUTICAL L (JENBURPH) financials
JENBURKT PHARMACEUTICAL L (JENBURPH) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.
Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]
- Market Cap: ₹421Cr.
- Current Price: ₹954
- Stock P/E: 11.8
- ROE: 20.2%
- ROCE: 27.0%
- Book Value: ₹464
- Dividend Yield: 2.17%
- 52W High / Low: ₹1,297/845
In Sep 2026, JENBURKT PHARMACEUTICAL L (JENBURPH) reported sales ₹48 Cr and net profit ₹10 Cr.
Annual TTM: sales ₹171 Cr, net profit ₹33 Cr.
Shareholding: Promoters 46.62% (Sep 2026), DIIs 0.03% (Sep 2026), Public 53.34% (Sep 2026), No. of Shareholders 7,351% (Sep 2026).
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 37 | 41 | 36 | 46 | 43 | 45 | 36 | 48 |
| YoY Sales growth | +3% | +6% | +9% | +11% | +17% | +9% | -0% | +6% |
| Expenses | 28 | 30 | 27 | 32 | 36 | 30 | 29 | 35 |
| Operating Profit | 9 | 11 | 9 | 13 | 7 | 14 | 6 | 13 |
| OPM % | 24% | 26% | 25% | 29% | 17% | 32% | 17% | 27% |
| Other Income | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 10 | 12 | 10 | 14 | 8 | 14 | 7 | 14 |
| Tax % | 32% | 28% | 23% | 29% | 29% | 21% | 13% | 29% |
| Net Profit | 7 | 9 | 8 | 10 | 6 | 11 | 6 | 10 |
| EPS in Rs | 14.75 | 19.35 | 17.65 | 23.02 | 13.44 | 24.58 | 13.35 | 23.13 |
| Raw PDF | — | — | — | — | — | — | — | — |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 119 | 109 | 124 | 137 | 142 | 152 | 169 | 171 |
| Sales growth | -3% | -8% | +13% | +10% | +4% | +7% | +11% | +8% |
| Expenses | 99 | 89 | 97 | 106 | 109 | 111 | 125 | 131 |
| Operating Profit | 20 | 20 | 27 | 30 | 33 | 40 | 44 | 41 |
| OPM % | 17% | 18% | 22% | 22% | 23% | 27% | 26% | 24% |
| Other Income | 4 | 4 | 5 | 5 | 5 | 7 | 6 | 6 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
| Profit before tax | 21 | 22 | 30 | 33 | 35 | 44 | 47 | 43 |
| Tax % | 30% | 24% | 25% | 25% | 26% | 27% | 25% | — |
| Net Profit | 15 | 16 | 22 | 25 | 26 | 32 | 35 | 33 |
| EPS in Rs | 32.40 | 35.95 | 48.59 | 55.76 | 58.87 | 72.64 | 78.72 | 74.50 |
| Dividend Payout % | 25% | 28% | 25% | 26% | 26% | 25% | 26% | — |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 |
| Reserves | 75 | 94 | 113 | 118 | 141 | 167 | 193 | 201 |
| Borrowings | 3 | 5 | 7 | 3 | 0 | 4 | 2 | 2 |
| Other Liabilities | 21 | 17 | 18 | 16 | 19 | 19 | 26 | 28 |
| Total Liabilities | 104 | 120 | 143 | 141 | 164 | 195 | 225 | 235 |
| Fixed Assets | 12 | 11 | 11 | 10 | 10 | 15 | 19 | 74 |
| CWIP | 0 | 0 | 0 | 1 | 1 | 40 | 46 | 3 |
| Investments | 4 | 7 | 8 | 11 | 17 | 21 | 27 | 30 |
| Other Assets | 88 | 103 | 123 | 119 | 136 | 120 | 132 | 128 |
| Total Assets | 104 | 120 | 143 | 141 | 164 | 195 | 225 | 235 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 13 | 15 | 19 | 9 | 17 | 8 | 28 | 27 |
| Cash from Investing Activity | -11 | -3 | -19 | -1 | 3 | -1 | -17 | -19 |
| Cash from Financing Activity | -2 | -11 | -1 | -6 | -21 | -7 | -8 | -9 |
| Net Cash Flow | 0 | 1 | -0 | 3 | -1 | 0 | 3 | -2 |
| Free Cash Flow | 11 | 11 | 18 | 7 | 15 | 6 | 8 | 13 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 80% | 104% | 127% | 62% | 83% | 49% | 102% | 88% |
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 46.69% | 46.68% | 46.67% | 46.66% | 46.65% | 46.64% | 46.62% | 46.62% |
| DIIs | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.12% | 0.03% |
| Public | 53.20% | 53.20% | 53.21% | 53.22% | 53.24% | 53.24% | 53.27% | 53.34% |
| No. of Shareholders | 6,901 | 6,987 | 6,712 | 6,855 | 7,163 | 6,999 | 7,103 | 7,351 |
| Category | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 68 | 55 | 47 | 45 | 45 | 50 | 50 | 53 |
| Inventory Days | 99 | 120 | 92 | 115 | 92 | 103 | 109 | 154 |
| Days Payable | 66 | 58 | 56 | 83 | 67 | 75 | 100 | 91 |
| Cash Conversion Cycle | 101 | 117 | 83 | 77 | 70 | 78 | 59 | 115 |
| Working Capital Days | 35 | 32 | 17 | 16 | 31 | 36 | 31 | 41 |
| ROCE % | 37% | 26% | 24% | 26% | 27% | 26% | 27% | 27% |
Jenburkt Pharmaceutical L
₹421Cr.
₹954
₹1,297/845
11.8
Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]
Quarterly results
Profit & loss
Shareholding trend
Balance sheet
Cash flows
Key ratios
Frequently asked questions
What is the market cap of JENBURKT PHARMACEUTICAL L (JENBURPH)?
The reported market capitalisation for JENBURKT PHARMACEUTICAL L (JENBURPH) is ₹421Cr. on Fincrux. Figures may update with market data and filings.
What is the current share price of JENBURPH?
The current price shown for JENBURKT PHARMACEUTICAL L (JENBURPH) on Fincrux is ₹954 with a 52-week high/low of ₹1,297/845.
What is the P/E ratio of JENBURKT PHARMACEUTICAL L (JENBURPH)?
The stock P/E for JENBURKT PHARMACEUTICAL L (JENBURPH) is 11.8 on Fincrux, with ROE at 20.2% and ROCE at 27.0%.
What were JENBURPH latest quarterly results?
For Sep 2026, JENBURKT PHARMACEUTICAL L (JENBURPH) reported sales ₹48 Cr and net profit ₹10 Cr (figures in ₹ crore unless noted).
What are JENBURPH annual sales and net profit?
For TTM, JENBURKT PHARMACEUTICAL L (JENBURPH) shows sales of ₹171 Cr and net profit of ₹33 Cr on the Fincrux profit & loss statement.
Who owns JENBURKT PHARMACEUTICAL L (JENBURPH)?
Latest shareholding for JENBURKT PHARMACEUTICAL L (JENBURPH) on Fincrux: Promoters 46.62% (Sep 2026), DIIs 0.03% (Sep 2026), Public 53.34% (Sep 2026), No. of Shareholders 7,351% (Sep 2026).
Where can I find JENBURKT PHARMACEUTICAL L (JENBURPH) financials?
JENBURKT PHARMACEUTICAL L (JENBURPH) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.
Does Fincrux show JENBURPH balance sheet and cash flow?
Yes. The JENBURKT PHARMACEUTICAL L (JENBURPH) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.